It is not just the physical and emotional implications to the patients, but the increasing economic burden on healthcare systems around the world. The British Heart Foundation estimates that the healthcare costs in the UK alone associated with CVD to be up at £11bn.
As average life expectancy increases, so too does the expectation to remain physically active with a high quality of life for much longer. The freedom from reoperation or anti-rejection and anti-coagulation drugs allows patients to lead almost a completely normal life being physically active. It could also significantly reduce the economic consequences of this problem.
The results of Professor Francisco da Costa’s pioneering work at the Pontifical Catholic University of Paraná (PUCPR), and the Santa Casa hospital, Brazil, relating to CardioPure dCELL® pulmonary and aortic heart valves confirms the success of dCELL® in this field based on over 10 years of clinical data.